Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk

Among patients with colorectal cancer (CRC) treated with oxaliplatin (L-OHP)-based chemotherapy, delayed chemotherapy-induced nausea and vomiting (CINV) have not been well controlled. We pooled data from two prospective observational studies in Japan and one phase III clinical trial to assess whethe...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2021-10, Vol.21 (1), p.1111-8, Article 1111
Main Authors: Shimokawa, Mototsugu, Hayashi, Toshinobu, Nishimura, Junichi, Satoh, Taroh, Fukunaga, Mutsumi, Matsui, Reiko, Tsuji, Yasushi, Mizuki, Fumitaka, Kogawa, Takahiro
Format: Article
Language:English
Subjects:
Age
Aged
Antiemetics
Antiemetics - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Cancer
Cancer therapies
Capecitabine - adverse effects
Chemotherapy
Clinical Trials, Phase III as Topic
Colorectal cancer
Colorectal carcinoma
Colorectal Neoplasms - drug therapy
Complications and side effects
Disease prevention
Drug therapy
Drug Therapy, Combination
Female
Fluorouracil - adverse effects
Habits
Humans
Japan
Leucovorin - adverse effects
Male
Middle Aged
Motion sickness
Nausea
Nausea - chemically induced
Nausea - drug therapy
Neurokinin
Neurokinin NK1 receptors
Neurokinin-1 Receptor Antagonists - therapeutic use
Observational Studies as Topic
Organoplatinum Compounds - adverse effects
Oxaliplatin
Oxaloacetates - adverse effects
Patients
Prevention
Prophylaxis
Randomized Controlled Trials as Topic
Regression analysis
Risk Factors
Sex Factors
Steroids
Vomiting
Vomiting - chemically induced
Vomiting - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Among patients with colorectal cancer (CRC) treated with oxaliplatin (L-OHP)-based chemotherapy, delayed chemotherapy-induced nausea and vomiting (CINV) have not been well controlled. We pooled data from two prospective observational studies in Japan and one phase III clinical trial to assess whether delayed CINV could be controlled with a combination of three antiemetics adding a neurokinin-1 receptor antagonist and identified individual risk factors, using an inverse probability treatment-weighted analysis. A total of 661 patients were evaluable in this study (median age: 64 years; 391 male, and 270 female). 3 antiemetics controlled delayed nausea (33.18% vs. 42.25%; p = 0.0510) and vomiting (4.15% vs. 16.08%; p 
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-021-08860-y